» Articles » PMID: 24390544

The Microbial Metabolite Butyrate Regulates Intestinal Macrophage Function Via Histone Deacetylase Inhibition

Overview
Specialty Science
Date 2014 Jan 7
PMID 24390544
Citations 905
Authors
Affiliations
Soon will be listed here.
Abstract

Given the trillions of microbes that inhabit the mammalian intestines, the host immune system must constantly maintain a balance between tolerance to commensals and immunity against pathogens to avoid unnecessary immune responses against otherwise harmless bacteria. Misregulated responses can lead to inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. The mechanisms by which the immune system maintains this critical balance remain largely undefined. Here, we demonstrate that the short-chain fatty acid n-butyrate, which is secreted in high amounts by commensal bacteria, can modulate the function of intestinal macrophages, the most abundant immune cell type in the lamina propria. Treatment of macrophages with n-butyrate led to the down-regulation of lipopolysaccharide-induced proinflammatory mediators, including nitric oxide, IL-6, and IL-12, but did not affect levels of TNF-α or MCP-1. These effects were independent of toll-like receptor signaling and activation of G-protein-coupled receptors, two pathways that could be affected by short-chain fatty acids. In this study, we provide several lines of evidence that suggest that these effects are due to the inhibition of histone deacetylases by n-butyrate. These findings elucidate a pathway in which the host may maintain tolerance to intestinal microbiota by rendering lamina propria macrophages hyporesponsive to commensal bacteria through the down-regulation of proinflammatory effectors.

Citing Articles

Alleviates Colitis by Regulating FXR-NLRP3 Mediated Macrophage Pyroptosis.

Yang L, Li W, Zhao Q, Mo Q, Liu T, Cao H J Inflamm Res. 2025; 18:3161-3176.

PMID: 40065908 PMC: 11891491. DOI: 10.2147/JIR.S504957.


Integrated microbiome and metabolome analysis reveals altered gut microbial communities and metabolite profiles in dairy cows with subclinical mastitis.

Yu J, Liu C, Wang D, Wan P, Cheng L, Yan X BMC Microbiol. 2025; 25(1):115.

PMID: 40033186 PMC: 11877966. DOI: 10.1186/s12866-025-03810-1.


Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review.

Todor S, Ichim C Children (Basel). 2025; 12(2).

PMID: 40003268 PMC: 11854176. DOI: 10.3390/children12020166.


The Interplay of Nutrition, the Gut Microbiota and Immunity and Its Contribution to Human Disease.

Dawson S, Todd E, Ward A Biomedicines. 2025; 13(2).

PMID: 40002741 PMC: 11853302. DOI: 10.3390/biomedicines13020329.


From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes.

Blok L, Hanssen N, Nieuwdorp M, Rampanelli E Metabolites. 2025; 15(2).

PMID: 39997763 PMC: 11857261. DOI: 10.3390/metabo15020138.


References
1.
Cerf-Bensussan N, Gaboriau-Routhiau V . The immune system and the gut microbiota: friends or foes?. Nat Rev Immunol. 2010; 10(10):735-44. DOI: 10.1038/nri2850. View

2.
Sokol H, Seksik P, Furet J, Firmesse O, Nion-Larmurier I, Beaugerie L . Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15(8):1183-9. DOI: 10.1002/ibd.20903. View

3.
Smith P, Howitt M, Panikov N, Michaud M, Gallini C, Bohlooly-Y M . The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013; 341(6145):569-73. PMC: 3807819. DOI: 10.1126/science.1241165. View

4.
Scheppach W . Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci. 1996; 41(11):2254-9. DOI: 10.1007/BF02071409. View

5.
Hamer H, Jonkers D, Vanhoutvin S, Troost F, Rijkers G, de Bruine A . Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr. 2010; 29(6):738-44. DOI: 10.1016/j.clnu.2010.04.002. View